NOVAVAX INC (NVAX) Q3 2025 10-Q Quarterly Report
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR NOVAVAX INC (NVAX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
NOVAVAX INC Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Q3 revenue $70.4M, down $14.1M YoY from $84.5M; product sales $13.4M vs $41.5M, licensing up $14.0M to $57.0M
- • Q3 net loss $202.4M vs $121.3M YoY; operating expenses rose 13.7% to $248.5M; impairment loss $97M and $28.7M debt extinguishment loss impacted results
- • Best segment Q3 licensing revenue (Sanofi $48.3M + Takeda $6.4M), worst product sales declined $28.1M due to Nuvaxovid sales decrease
- • Operating cash flow impacted by asset impairment and lower product sales; capital deployment included sale agreement of corporate HQ assets
- • Management expects reduced R&D and SG&A spend for remainder of 2025 with ongoing restructuring; milestone payments of $50M and $175M received under Sanofi CLA
Risk Factors
- • New FDA framework requiring placebo-controlled trials for COVID-19 vaccines in healthy under 65 population, increasing expenses and approval delays
- • PMC post-approval clinical trial amendments requested by FDA, potential cost increases subject to Sanofi negotiations and reimbursement terms
- • Regulatory risk from expiration of U.S. and WHO COVID-19 Public Health Emergency designations, removing shortened regulatory timelines
- • Operational risk from evolving COVID-19 variants and regulatory priorities affecting vaccine development and clinical trial designs
- • Concentration risk from dependency on collaboration with Sanofi for marketing authorization and regulatory discussions after marketing authorization transfer
Get deeper insights on NOVAVAX INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.